

LETTERS: NEW OBSERVATION

HOMER-3 Antibodies Were Not Detected in Two German Cohorts of Patients with Multiple System Atrophy

Multiple system atrophy (MSA) is a neurodegenerative disease with progressive disability and reduced life expectancy.¹ Patients suffer from predominant cerebellar or parkinsonian symptoms combined with autonomic failure. In recent years, an increasing number of autoantibodies were detected that can evoke syndromes mimicking neurodegenerative diseases.² In this group of newly discovered antibodies, HOMER-3 autoantibodies were reported to mimic an MSA phenotype with cerebellar ataxia, dysautonomia, rapid eye movement (REM) sleep behavior disorder, and a hot cross bun sign on structural MRI in an Asian population.³ In a cohort of 750 Asian patients suspected for autoimmune cerebellar ataxia, six patients had HOMER-3 antibodies in the serum, and two of these six also in cerebrospinal fluid (CSF).³ One-third (2/6) of these HOMER-3-positive patients presented with clinical and magnetic resonance imaging (MRI) signs compatible with MSA. Interestingly, these patients presented the HOMER-3 antibody only in serum.³ Because this HOMER-3-antibody related disease is a potentially treatable condition, our current study aimed to identify the prevalence of HOMER-3 autoantibodies in clinically diagnosed MSA patients.

© 2022 The Authors. *Movement Disorders* published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

This is an open access article under the terms of the [Creative Commons Attribution](#) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Key Words: HOMER-3, multiple system atrophy, autoimmunity, autoantibody, anti-neuronal antibody

***Correspondence to:** Dr. Martin Klietz, Department of Neurology Hannover Medical School Carl-Neuberg-Str. 1, 30625 Hannover, Germany; E-mail: klietz.martin@mh-hannover.de

Relevant conflicts of interest/financial disclosures: There were no conflicts of interest relevant to this study to declare.

Funding agencies: The authors received no specific funding for this study. J.L. and S.K. were funded by the Deutsche Forschungsgemeinschaft (DFG) under Germany's Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy-ID 390857198). J.L. reports speaker fees from Bayer Vital, Biogen, and Roche, consulting fees from Axon Neuroscience and Biogen, author fees from Thieme medical publishers and W. Kohlhammer medical publishers. In addition, he reports compensation for serving as chief medical officer for MODAG, is beneficiary of the phantom share program of MODAG and is inventor in a patent "Pharmaceutical Composition and Methods of Use" (EP 22159408.8) filed by MODAG, all activities outside the submitted work.

Received: 8 July 2022; **Accepted:** 14 July 2022

Published online in Wiley Online Library
([wileyonlinelibrary.com](https://www.wileyonlinelibrary.com)). DOI: 10.1002/mds.29185

Therefore, patients of European origin from two German biobank cohorts, diagnosed according to the Gilman criteria for clinical diagnosis of possible or probable MSA⁴ were analyzed with a research-grade HOMER-3 antibody assay (Euroimmun, Lübeck, Germany).^{3,5} In total, 59 patients (25 female) with a mean age of 61.5 ± 8.4 were included in this study. Of these, 33 presented with a cerebellar (MSA-C) and 26 with a parkinsonian phenotype (MSA-P). The mean disease duration was 3.7 ± 2.3 years. In none of these patients we were able to detect HOMER-3 antibodies in serum.

The preexisting data indicate that HOMER-3 antibody associated cerebellar ataxia may be a rare, but potentially treatable differential diagnosis for MSA.^{3,5,6} Based on our data, systematic screening of all patients with clinically suspected MSA cannot be generally recommended. The frequency of HOMER-3 positive patients needs to be determined in larger MSA cohorts of diverse ethnicities, and the specific clinical and imaging phenotype of this autoimmune disease needs to be further elaborated to identify specific features, which would encourage HOMER-3 testing in individual patients not to be missed for individualized therapies.⁷ ■

Acknowledgment: We thank Euroimmun, Lübeck, Germany for the generous supply with the antibody assay. Open Access funding enabled and organized by Projekt DEAL.

Ethics Statement

We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this work is consistent with those guidelines. We obtained approval of the local institutional review boards for this work (MHH: 8666_BO_K_2019; LMU: 18-353). Written informed consent was obtained from every participant.

Martin Klietz, MD,^{1*}  Sabrina Katzdobler, MD, Johannes Levin, MD,^{2,3,4} Florian Wegner, MD,¹ Matthias Höllerhage, MD,¹ Franziska Hopfner, MD,¹ Lea Krey, MD,¹ Johanne Heine, MD,¹ Thomas Skripuletz, MD,¹ and Günter U. Höglinger, MD¹ 
¹Department of Neurology, Hannover Medical School, Hannover, Germany, ²Department of Neurology, Ludwig-Maximilians-University of Munich, Munich, Germany, ³German Center for Neurodegenerative Diseases (DZNE), Munich, Germany, and ⁴Munich Cluster for Systems Neurology, Munich, Germany

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

References

1. Pérez-Soriano A, Giraldo DM, Ríos J, Muñoz E, Compta Y, Martí MJ, et al. Progression of motor and non-motor symptoms in multiple system atrophy: a prospective study from the Catalan-MSA registry. *J Parkinsons Dis* 2021;11:685–694.

2. Balint B, Vincent A, Meinck H-M, Irani SR, Bhatia KP. Movement disorders with neuronal antibodies: syndromic approach, genetic parallels and pathophysiology. *Brain* 2017;141:13–36.
3. Liu M, Ren H, Fan S, Zhang W, Xu Y, Zhao W, et al. Neurological autoimmunity associated with Homer-3 antibody. *Neurol Neuroimmunol Neuroinflamm* 2021;8:e1077.
4. Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, et al. Second consensus statement on the diagnosis of multiple system atrophy. *Neurology* 2008;71:670–676.
5. Xu X, Ren H, Li L, Wang J, Fechner K, Guan H. Anti-Homer-3 antibody associated cerebellar ataxia: a rare case report and literature review. *J Neuroimmunol* 2019;330:155–158.
6. Höftberger R, Sabater L, Ortega A, Dalmau J, Graus F. Patient with Homer-3 antibodies and Cerebellitis. *JAMA Neurol* 2013;70:506–509.
7. Mulroy E, Balint B, Bhatia KP. Homer-3 antibody disease: a potentially treatable MSA- C mimic. *Mov Disord Clin Pract* 2022;9:178–182.

SGML and CITI Use Only
DO NOT PRINT

Author Roles

(1) Research project: A. Conception, B. Organization, C. Execution; (2) Statistical Analysis: A. Design, B. Execution, C. Review and Critique; (3) Manuscript Preparation: A. Writing of the First Draft, B. Review and Critique.: M.K.: 1A, 1B, 1C, 2A, 2B, 3A.: S.K.: 1C, 2C, 3B: J.L.: 1B, 2C, 3B: F.W.: 1B, 2C, 3B: L.K.: 1C, 3B.: M.H.: 1C, 3B.: F.H.: 1C, 3B.: J.H.: 1C, 3B.: T.S.: 1A, 1B, 1C, 2A, 2C, 3B.: G.U.H.: 1A, 1B, 1C, 2A, 2C, 3B

Financial Disclosures for the previous 12 Months

The authors do not have any relevant disclosures concerning this publication.